Institutional investors hold a majority ownership of ACHN through the 83.16% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended December 2017, these large investors purchased a net $6.8 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CANDRIAM BELGIUM SA Bought 215.0 Thousand shares of Achillion Pharmaceuticals...